Effects of two oral contraceptives on plasma levels of insulin-like growth factor I (IGF-I) and growth hormone (hGH)

A Balogh, E Kauf, R. Vollanth, G Gräser, G Klinger, M. Öettel, M Oettel
Contraception · 2000 · vol. 62(5) , pp. 259–269 · doi:10.1016/s0010-7824(00)00176-1 · PMID:11172797 · W2018281370
RCT OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-10 ⓘ

This study investigated the impact of two oral contraceptives on plasma levels of insulin-like growth factor I (IGF-I) and growth hormone (hGH).

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

UNLABELLED: In 18 healthy women, the effect of two oral contraceptives (OCs) on insulin-like growth factor (IGF-I) and its binding protein-3 (IGFBP-3) and growth hormone (hGH) plasma level were studied before and after intake of either of two OC formulations over 21 days, one containing 2 mg dienogest and 0.03 mg ethinylestradiol (group A) and the other 0.125 mg levonorgestrel and 0.03 mg ethinylestradiol (group B). There was a reduction of the mean IGF-I concentration of 30% (p = 0.008) in the women receiving dienogest-containing pills and 12% (p = 0.006) in women taking the levonogestrel-containing preparation. This difference between drug groups was statistically significant (p = 0.002). A correlation between the control values and the basal-treatment difference (r = 0.945; p = 0.000) was observed only in women of group A. Between basal and treatment cycles the mean plasma levels of hGH remained unchanged in both groups tested, but the 23.5-h integrated mean hGH plasma concentrations (AUC(0-23.5h)) were significantly elevated by 36% (p = 0.016) in comparison to basal values before treatment only in women receiving the levonorgestrel-containing pills. Also, in the women who received the dienogest-containing preparation, the changes of integrated mean plasma level were inversely associated with the control values (r = -0.723; p = 0.025). Neither in group A nor in group B was the mean plasma level of IGFB-3 changed. IN CONCLUSION: the results of the present analysis indicate that hormonal contraceptives can modulate the GH and IGF-I-axis in the reproductive age. Probably the androgenic progestogen levonorgestrel (0.125 mg/day) opposes the estrogen-induced action. In the women who took the dienogest-containing formulations (anti-androgenic progestogen-group A), the extent of individual changes (hGh and IGF-I) depends on the basal level prior to pill intake. Further studies, especially of long-term intake of OCs, are necessary to confirm these results and to assess the practical relevance for possible effects on connective tissue and bone.

My notes (saved in your browser only)

MeSH descriptors

Contraceptive Agents, Female Human Growth Hormone Insulin-Like Growth Factor I Nandrolone Contraceptive Agents, Female Contraceptives, Oral, Combined Contraceptives, Oral, Combined Ethinyl Estradiol Ethinyl Estradiol Female Human Growth Hormone Human Growth Hormone Humans Insulin-Like Growth Factor Binding Protein 3 Insulin-Like Growth Factor Binding Protein 3 Insulin-Like Growth Factor Binding Protein 3 Insulin-Like Growth Factor I Insulin-Like Growth Factor I Levonorgestrel Levonorgestrel

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

References (36)

Cited by (2)

Source provenance

openalex
last seen: 2026-05-11T05:54:30.111693+00:00
pubmed
last seen: 2026-10-08T20:59:46.244316+00:00
unpaywall
last seen: 2026-10-20T06:27:24.728081+00:00
License: CC0 · commercial use OK